期刊文献+

艾司西酞普兰与帕罗西汀治疗老年脑卒中后抑郁的对照研究 被引量:12

Comparative Study of Escitalopram and Paroxetine in Treatment of Elderly Post-Stroke Depression
下载PDF
导出
摘要 目的探讨艾司西酞普兰与帕罗西汀治疗老年脑卒中后抑郁的临床疗效及安全性。方法将68例患者随机分为A组和B组,各34例,A组口服草酸艾司西酞普兰,B组口服帕罗西汀。两组于治疗前和治疗后1,2,4,8周末采用汉密尔顿抑郁量表(HAMD)评定疗效,不良反应量表(TESS)评定不良反应。结果两组治疗后HAMD评分均较治疗前显著下降,差异有统计学意义(P<0.01);A组和B组疗效总有效率分别为94.12%和91.18%,不良反应率分别为35.29%和38.24%,差异均无统计学意义(P>0.05)。结论艾司西酞普兰与帕罗西汀治疗老年脑卒中后抑郁的疗效相当,但艾司西酞普兰起效更快,不良反应更轻,适合作为老年脑卒中后抑郁患者的一线用药。 Objective To evaluate efficacy and safety of escitalopram and paroxetine in the treatment of post stroke depression in eider patients. Methods Sixty eight elder patients with post stroke depression were randomly divided into the group A and B, 34 cases in each group. The group A took oral escitalopram oxalate and the group B took oral paroxetine. The efficacies of before treatment and in post treatment 1, 2, 4, 8 weeks were evaluated according to the Hamilton rating scale for depression(HAMD), and the adverse reactions according to the treatment emergent side effect scale(TESS). Results The scores of HAMD after treatment were significantly decreased than before treatment in the two groups with statistical difference (P〈0. 01). The total effective rates in both two groups were 94.12% and 91. 18%, and the rates of adverse reactions were 35.29% and 38.24%, respectively, which were not statistically different between the two groups. Conclusion The efficacy of escitalopram and paroxetine in the treatment of post stroke depression in elder patients is similar, but escitalopram has faster effect and milder adverse reactions than paroxetine, and is suitable to be used as the first line drug.
出处 《中国药业》 CAS 2012年第19期75-76,共2页 China Pharmaceuticals
关键词 艾司西酞普兰 帕罗西汀 老年脑卒中后抑郁 escitalopram paroxetine post stroke depression
  • 相关文献

参考文献7

二级参考文献28

  • 1许政援 沈家鲜 吕静 等.儿童发展心理学[M].长春:吉林教育出版社,1991.84-85.
  • 2[1]Mork A,Kreilgaard M,Sanchez C.The R-enantiomer of citalopram counteracts escitalopram-induced increase in extraeellular 5-HT in the frontal cortex of freely moving tars[J].Neuropharmacology,2003,45(2):167-173
  • 3[2]Baldwin DS.Escitalopram:effieancy and tolerability in the treatment of depression[J].Hosp Med,2003,163 (11):668-671
  • 4[3]Montgomery SA,Huusom AK,Bothmer J.A randomized study comparing escitalopram with venlafaxine XR in primary eare patients with major depressive disorder[J].Neuropsychobiology,2004,50 (1):57-64
  • 5[4]Sanchez C,Bergqvist PB,Brennum LT,et al.Escitalopram,the S-(+)-enantiomer of citalopram,is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities[J].Psychopharmacology(Berl),2003,167 (4):353-362
  • 6[5]Sanchez C.R-citalopram attenuates anxiolytic effects of cscitalopram in a rat ultrasonic vocalization model[J].Eur J Pharmacol,2003,464(2-3):155-158
  • 7[6]William J.Burke:Esciralopram[J].Expert Opinion on Investigarional Drugs,2002,11 (10):1477-1486
  • 8[7]Llorea PM.Brousse G.Schwan R.Escitalopram for treatment of major depressive disorder in adults[J].Encephale,2005,31(4 Pt 1):490-501
  • 9[8]Kasper S,Spadone C,Verpillat P,et al.Onset of action of escitalopram compared with other antidepressants:results of a pooled analysis[J].Int Clin Psychopharmacol,2006.21(2):105-110
  • 10[9]Kennedy SH.Andersen HF.Lam RW.Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR:a meta-anal.ysis[J].Psychiatry Neurosci,2006,31(2):122-131

共引文献33060

同被引文献102

引证文献12

二级引证文献181

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部